Content Team

Key milestone marks transition of CHARM into a clinical stage company   Initial data anticipated in 2027 LONDON – 7 October 2026 -- CHARM Therapeutics (“CHARM”, “The Company”), a clinical-stage biotechnology company addressing resistance in acute myeloid leukemia (AML) with…

LONDON – 18 August 2026 -- CHARM Therapeutics (“CHARM”, “The Company”), a biotechnology company addressing resistance in acute myeloid leukemia (AML) with a best-in-class menin inhibitor, announces the formation of its Clinical Advisory Board to support the advancement of CHM-029…

AI-discovered candidate CHM-029 demonstrates robust, dose-dependent tumor regression in pre-clinical AML models and retains potency against all known resistance mutations First-in-human trials expected to begin in Q2 2026 LONDON – 13 November 2025 — CHARM Therapeutics (“CHARM”, “The Company”), today…

LONDON – 8 September 2025 — CHARM Therapeutics (“CHARM”, “The Company”), announces the appointment of Dr Erkut Bahceci as Chief Medical Officer. Erkut’s appointment follows CHARM’s $80 million Series B financing, co-led by NEA and SR One, to advance its…

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla Ventures CHARM’s AI-designed menin inhibitor overcomes resistance mutations with the potential to deliver superior efficacy, durability and safety; clinical development expected to start 1Q26…

LONDON – 10 September 2024 — CHARM Therapeutics (“CHARM”, “The Company”), an AI-based biotechnology company discovering impactful medicines through protein-ligand intelligence, today announces the appointment of Dr Beverley Carr as Chief Business Officer. Beverley will focus on driving the value…

LONDON – 30 April 2024 — CHARM Therapeutics (“CHARM”, “The Company”), a protein-ligand intelligence company turning prediction into impactful medicines, today announces the appointment of Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development. In this role, he…